NASDAQ:HUGE - FSD Pharma Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $11.00
  • Forecasted Upside: 528.57 %
  • Number of Analysts: 1
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$1.75
▼ -0.19 (-9.79%)
1 month | 3 months | 12 months
Get New FSD Pharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for HUGE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for HUGE

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$11.00
▲ +528.57% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for FSD Pharma in the last 3 months. The average price target is $11.00, with a high forecast of $11.00 and a low forecast of $11.00. The average price target represents a 528.57% upside from the last price of $1.75.
Buy
The current consensus among 1 contributing investment analysts is to buy stock in FSD Pharma.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/11/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/10/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/9/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/7/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/5/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/2/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/20/2020Brookline Capital ManagementInitiated CoverageBuy$11.00N/A
i
(Data available from 3/4/2016 forward)
FSD Pharma logo
FSD Pharma Inc., through its subsidiary, FV Pharma Inc., produces medical cannabis in Canada. The company focuses on the development of indoor grown pharmaceutical grade cannabis; and research and development of various cannabinoid-based treatments for central nervous system disorders and autoimmune diseases of the skin, GI tract, and musculoskeletal system, such as chronic pain. FSD Pharma Inc. has strategic alliance agreements with SciCann Therapeutics Inc., CannTab Therapeutics, and Solarvest BioEnergy Inc. The company was founded in 1998 and is headquartered in Toronto, Canada.
Read More

Today's Range

Now: $1.75
$1.67
$1.90

50 Day Range

MA: $2.30
$1.94
$3.87

52 Week Range

Now: $1.75
$1.28
$14.00

Volume

46,118 shs

Average Volume

3,545,908 shs

Market Capitalization

$33.53 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.39

Frequently Asked Questions

What sell-side analysts currently cover shares of FSD Pharma?

The following Wall Street research analysts have issued reports on FSD Pharma in the last year: Brookline Capital Management.
View the latest analyst ratings for HUGE.

What is the current price target for FSD Pharma?

1 Wall Street analysts have set twelve-month price targets for FSD Pharma in the last year. Their average twelve-month price target is $11.00, suggesting a possible upside of 525.0%. Brookline Capital Management has the highest price target set, predicting HUGE will reach $11.00 in the next twelve months. Brookline Capital Management has the lowest price target set, forecasting a price of $11.00 for FSD Pharma in the next year.
View the latest price targets for HUGE.

What is the current consensus analyst rating for FSD Pharma?

FSD Pharma currently has 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe HUGE will outperform the market and that investors should add to their positions of FSD Pharma.
View the latest ratings for HUGE.

What other companies compete with FSD Pharma?

How do I contact FSD Pharma's investor relations team?

FSD Pharma's physical mailing address is 520 WILLIAM STREET, COBOURG A6, K9A 3A5. The company's listed phone number is (416) 854-8884 and its investor relations email address is [email protected] The official website for FSD Pharma is fsdpharma.com.